Sfmg LLC Purchases Shares of 2,147 Bruker Co. (NASDAQ:BRKR)

Sfmg LLC acquired a new position in Bruker Co. (NASDAQ:BRKR) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,147 shares of the medical research company’s stock, valued at approximately $202,000.

Several other institutional investors and hedge funds have also recently modified their holdings of BRKR. Diversified Trust Co increased its position in shares of Bruker by 51.8% in the third quarter. Diversified Trust Co now owns 6,373 shares of the medical research company’s stock valued at $397,000 after buying an additional 2,174 shares in the last quarter. Citigroup Inc. raised its position in Bruker by 1.9% during the third quarter. Citigroup Inc. now owns 59,047 shares of the medical research company’s stock worth $3,679,000 after acquiring an additional 1,079 shares during the period. VisionPoint Advisory Group LLC lifted its holdings in Bruker by 145.0% during the third quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 303 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its position in shares of Bruker by 93.8% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 34,026 shares of the medical research company’s stock worth $2,120,000 after purchasing an additional 16,466 shares during the last quarter. Finally, Canandaigua National Bank & Trust Co. acquired a new position in shares of Bruker during the 4th quarter worth about $223,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 2.1 %

NASDAQ BRKR traded down $1.34 during trading hours on Monday, reaching $63.41. The company had a trading volume of 794,040 shares, compared to its average volume of 994,960. Bruker Co. has a 1-year low of $53.79 and a 1-year high of $94.86. The stock has a market capitalization of $9.22 billion, a P/E ratio of 23.55, a price-to-earnings-growth ratio of 2.19 and a beta of 1.20. The stock has a 50-day moving average of $68.33 and a 200 day moving average of $76.65. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. The firm had revenue of $721.70 million for the quarter, compared to analyst estimates of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 EPS. As a group, research analysts anticipate that Bruker Co. will post 2.66 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 17th. Shareholders of record on Monday, June 3rd were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 3rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.32%. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Wall Street Analyst Weigh In

BRKR has been the subject of several research reports. The Goldman Sachs Group cut their price objective on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research note on Tuesday, July 9th. Jefferies Financial Group initiated coverage on Bruker in a report on Monday, June 3rd. They issued a “buy” rating and a $85.00 price objective on the stock. Stifel Nicolaus dropped their target price on shares of Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a report on Monday, May 20th. Citigroup dropped their price objective on shares of Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Wednesday, July 10th. Finally, Bank of America dropped their price target on Bruker from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Monday, May 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $81.78.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.